SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

10 Feb 2026 Evaluate
The company witnessed a 10.47% growth in the revenue at Rs. 4397.09 millions for the quarter ended December 2025 as compared to Rs. 3980.32 millions during the year-ago period.A big decline of -60.14% was reported for the quarter ended December 2025 to Rs. 404.17  millions from Rs. 1013.94 millions of corresponding previous quarter.Operating profit for the quarter ended December 2025 decreased to 849.79 millions as compared to 902.82 millions of corresponding quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 4397.09 3980.32 10.47 12467.35 11484.78 8.56 14768.37 15585.80 -5.24
Other Income 80.52 39.06 106.14 177.07 130.45 35.74 205.09 125.44 63.50
PBIDT 849.79 902.82 -5.87 2840.50 2845.89 -0.19 3428.08 4744.65 -27.75
Interest 67.90 22.16 206.41 167.14 59.49 180.95 82.96 139.97 -40.73
PBDT 781.89 1438.44 -45.64 2673.36 3550.44 -24.70 4109.16 4604.68 -10.76
Depreciation 239.17 162.99 46.74 666.43 486.51 36.98 655.42 596.99 9.79
PBT 542.72 1275.45 -57.45 2006.93 3063.93 -34.50 3453.74 4007.69 -13.82
TAX 138.55 261.51 -47.02 501.08 747.00 -32.92 859.48 1011.73 -15.05
Deferred Tax -13.51 12.27 -210.11 -19.77 69.84 -128.31 122.95 15.87 674.73
PAT 404.17 1013.94 -60.14 1505.85 2316.93 -35.01 2594.26 2995.96 -13.41
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 19.33 22.68 -14.80 22.78 24.78 -8.06 23.21 30.44 -23.75

Neuland Laboratories Share Price

17318.00 346.30 (2.04%)
07-May-2026 12:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.50
Dr. Reddys Lab 1310.35
Cipla 1373.30
Zydus Lifesciences 941.40
Lupin 2465.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×